{"id":209735,"name":"THE LIVINGSTON GROUP ON BEHALF OF INNOVATIVE VACCINE TECHNOLOGIES","slug":"the-livingston-group-on-behalf-of-innovative-vaccine-technologies","state":"DC","country":"United States of America","description":"Government and public relations consultants","totalSpending":430000,"filings":20,"yearlySpending":[{"year":2021,"income":90000},{"year":2022,"income":120000},{"year":2023,"income":120000},{"year":2024,"income":80000},{"year":2025,"income":20000}],"issues":[{"code":"MED","display":"Medical/Disease Research/Clinical Labs"},{"code":"BUD","display":"Budget/Appropriations"}],"firms":["MAGILL ASSOCIATES, LLC"],"lobbyists":["JOHN MAGILL"],"govEntities":["Army, Dept of (Other)","Defense, Dept of (DOD)","HOUSE OF REPRESENTATIVES","SENATE"],"sampleDescriptions":["FY'22 Appropriations for clinical trials for new vaccine platform","FY'22 Appropriations for clinical trials for new vaccine platform","FY'22 defense appropriations bill for the development of a synthetic vaccine","FY'22 defense appropriation bill for the development of a synthetic vaccine","FY'22 defense appropriation bill for the development of a synthetic vaccine"]}